|
|
|
| Influence of selenium supplementation for treating patients with polycystic ovary syndrome on their asymmetric dimethyl arginine level and their cardiac metabolic risk factors |
| Xinzhou District People's Hospital, Wuhan, Hubei Province, 430400 |
|
|
|
|
Abstract To investigate the effects of selenium supplementation for patients with polycystic ovary syndrome (PCOS) on their asymmetric dimethyl arginine (ADMA) level, their cardiac metabolic risk factors, and sex hormones levels. Methods: 76 patients with PCOS were randomly divided into study group (34 cases) and control group (32 cases). The patients in the study group were given oralselenium-enriched yeast tablet 60 μg every day for 12 weeks, and the patients in the control group were given placebo. The levels of fasting blood glucose (FBG), serum insulin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein AI (Apo-A1), and Apo-B 100 of the patients in the two groups were measured before and after intervention. The levels of serum total testosterone (T), sex hormone binding globulin (SHBG), and ADMA of the patients in the two groups were detected by ELISA. The insulin resistance (IR) of the patients in the two groups was calculated by homeostasis model assessment of IR (HOMA-IR). Results: After intervention, the levels of ADMA (52.4±18.64 ng/L) and T (0.49±0.31 ng/ml) of the patients in the study group were significantly lower than those (63.96±15.77 ng/L and 0.67±0.32 ng/ml) of the patients in the control group. The Apo-B100/Apo-A1 ratio (0.61±0.16) of the patients in the study group was significantly lower than that (0.67±0.19) of the patients in the control group (all P＜0.05). There were no significant differences in the levels of FBG, insulin, and other lipid, and the HOMA-IR value of the patients between the two groups (P＞0.05). Conclusion: The selenium supplementation for the patients with PCOS for 12 weeks has a positive effect on their ADMA and total T levels, and Apo B 100/Apo AI ratio, but which has no significant improvement on their other cardiac metabolic risk factors.
|
|
|
|
|
|
|
|
|
